Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry

March 30, 2020

Lauster, D., Klenk, S., Ludwig, K. et al.

Nature Nanotechnology 2020, doi: 10.1038/s41565-020-0660-2

Abstract

Multivalent interactions at biological interfaces occur frequently in nature and mediate recognition and interactions in essential physiological processes such as cell-to-cell adhesion. Multivalency is also a key principle that allows tight binding between pathogens and host cells during the initial stages of infection. One promising approach to prevent infection is the design of synthetic or semisynthetic multivalent binders that interfere with pathogen adhesion. Here, we present a multivalent binder that is based on a spatially defined arrangement of ligands for the viral spike protein haemagglutinin of the influenza A virus. Complementary experimental and theoretical approaches demonstrate that bacteriophage capsids, which carry host cell haemagglutinin ligands in an arrangement matching the geometry of binding sites of the spike protein, can bind to viruses in a defined multivalent mode. These capsids cover the entire virus envelope, thus preventing its binding to the host cell as visualized by cryo-electron tomography. As a consequence, virus infection can be inhibited in vitro, ex vivo and in vivo. Such highly functionalized capsids present an alternative to strategies that target virus entry by spike-inhibiting antibodies and peptides or that address late steps of the viral replication cycle.

View Publication

Topics: Virology, Monolith – MicroScale Thermophoresis, MST,  Publications

 

 

 

Previous Article
The three-fold axis of the HIV-1 capsid lattice is the species-specific binding interface for TRIM5α
The three-fold axis of the HIV-1 capsid lattice is the species-specific binding interface for TRIM5α

Up next
A glycan shield on chimpanzee CD4 protects against infection by primate lentiviruses (HIV/SIV)
A glycan shield on chimpanzee CD4 protects against infection by primate lentiviruses (HIV/SIV)

×

Sign up to receive
the latest NanoTemper news, product updates, event announcements and more

First Name
Last Name
Company Name
Country
State
Province
State
Region
State
Canton
Agree to Subscribe & Privacy Policy*
*I have fully read, understood and agree to the Privacy Policy. I accept the storing and processing of my personal data by NanoTemper as described in the Privacy Policy.

By completing this form, you provide us consent to contact you with educational content, news and information about our products, services and events. You may unsubscribe at any time.
Thank you!
Error - something went wrong!